Reed Jobs would rather talk about curing cancer than his last name

TechCrunch reports that Reed Jobs's biotech venture firm Yosemite has grown to seventeen team members since its launch three years ago, and is positioned to capitalize on blockbuster drugs losing patent protection around the same time. Jobs tells TechCrunch that artificial intelligence has become a huge part of the firm's strategy—and he says the pace of growth has even surprised him.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton